Skip to content

The Effect of PBM on the Electrical Activity of the Brain in Stroke Patients

The Effect of 850 nm Photobiomodulation Therapy (PBM) on the Electrical Activity of the Brain in Stroke Patients

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07323823
Acronym
PBM
Enrollment
66
Registered
2026-01-07
Start date
2025-12-31
Completion date
2026-12-31
Last updated
2026-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-stroke Aphasia

Brief summary

The Effect of Low-Level Light Therapy on the Electrical Activity of the Brain in Stroke Patients

Interventions

Experimental Group: Participants will receive iSyncWave transcranial photobiomodulation (tPBM) and speech therapy, with 20 minutes per modality per session, once daily, 5 days per week, for 4 weeks, totaling 20 sessions of combined intervention. During the intervention period, changes in concomitant medications and concurrent therapies will be monitored and recorded; any modifications to medications or therapies must be documented in detail.

OTHERcontrol group-receive speech therapy

Participants will receive speech therapy at a frequency of 20 minutes per session, once daily, 5 days per week, for 4 weeks, with a total of 20 sessions.

Sponsors

Pusan National University Yangsan Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patients diagnosed with ischemic or hemorrhagic stroke by a specialist. Patients in the recovery phase within 1 year after onset; those with confirmed clinical functional impairment upon assessment, who are conscious and able to cooperate with PBM stimulation and evaluations. Adult patients (≥ 18 years old) ,less than 80 years old,who have signed the informed consent form, or patients with proxy consent.

Exclusion criteria

* Individuals with photosensitive skin at risk of developing urticaria or dermatitis. Patients judged to have an unstable surgical site following hemorrhagic stroke-related surgery. Pregnant or lactating individuals. Individuals with a history of seizures. Individuals who have participated in clinical studies twice or more in the same year or in other clinical studies within 6 months. Other individuals with clinically significant findings deemed medically inappropriate for the study by the principal investigator or responsible researcher.

Design outcomes

Primary

MeasureTime frame
electroencephalography (EEG)Change in from baseline to post 20 sessions (up to approximately 4 weeks) α-Wave Increased amplitude, β-Wave moderate amplitude enhancement and θ-Wave Decreased excessive amplitude indicate functional recovery.

Secondary

MeasureTime frame
Boston Naming Test (BNT)Change in Boston Naming Test from baseline to post 20 sessions (up to approximately 4 weeks), Higher scores indicate better naming ability(Total score range: 0-60 points).
K-MMSE (Korean-Mini-Mental State Examination)Change in K-MMSE (Korean-Mini-Mental State Examination) from baseline to post 20 sessions (up to approximately 4 weeks), Higher scores indicate better global cognitive function(Total score range: 0-30 points).
K-MoCA (Korean-Montreal Cognitive Assessment)Change in K-MoCA (Korean-Montreal Cognitive Assessment) from baseline to post 20 sessions (up to approximately 4 weeks), Higher scores indicate better cognitive function(Total score range: 0-30 points).
Korean-Western Aphasia Battery(K-WAB)Change in Korean-Western Aphasia Battery from baseline to post 20 sessions (up to approximately 4 weeks), Higher scores indicate better language function(Total score range: 0-100 points).
Beck Depression InventoryChange in Beck Depression Inventory from baseline to post 20 sessions (up to approximately 4 weeks), Lower scores indicate milder depression (The total score range is 0-63 points).
EuroQol 5-Dimension Questionnaire(EQ-5D)Change in EuroQol 5-Dimension Questionnaire(EQ-5D) from baseline to post 20 sessions (up to approximately 4 weeks), Higher scores indicate better quality of life(Total score range: -0.171 ~ 1.000 points).
CDR ( Clinical Dementia Rating Scale)Change in CDR ( Clinical Dementia Rating Scale) from baseline to post 20 sessions (up to approximately 4 weeks), Lower scores indicate better cognitive function(Total score range: 0-18 points).

Contacts

Primary ContactIl Yong Shin
rmshin01@gmail.com010-6535-0310

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026